Fujifilm has purchased Merck's contract manufacturing sites for biologics in North Carolina and in Northeast England for $490 M.
Fuji says the acquisition will enhance its pharma group profile - an area it is trying to build as it diversifies its holdings away from the shrinking photo paper business. Fierce Biotech notes that it is ironic that Fuji views pharma as an atttractive diversification at a time when many Big Pharma companies are diversifiying into other industries like animal health, consumer products and the like.
Maybe the grass is greener looking through the eye of a digital camera?
Posted by Bruce Lehr March 2nd 2011.